ASCO24: Regeneron’s Bispecific Antibody Falls Flat in Early Study

Regeneron Pharmaceuticals on Thursday released early data from the ongoing Phase I/II study of its investigational bispecific antibody REGN7075, demonstrating underwhelming treatment response results in patients with advanced solid tumors.